Regeneron Pharmaceuticals (REGN) Operating Margin: History & Chart

Regeneron Pharmaceuticals, Inc.(REGN)

Biotechnology · Tarrytown, NY

$810.31+0.00 (+0.00%)

Delayed quote: Sep 8, 2026, 4:00 PM EDT

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Tarrytown, NY

15,410 employees

www.regeneron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard S. Schleifer

View full financials

REGN Operating Margin Metrics

OPERATING MARGIN

25.56%

OPERATING MARGIN AVG TTM

26.06%

OPERATING MARGIN AVG 3Y

27.73%

OPERATING MARGIN AVG 5Y

33.42%

OPERATING MARGIN AVG 10Y

33.68%

OPERATING MARGIN AVG 15Y

33.47%

OPERATING MARGIN AVG 20Y

19.71%

CURRENT VS TTM AVG

-1.93%

CURRENT VS 3Y AVG

-7.83%

CURRENT VS 5Y AVG

-23.52%

CURRENT VS 10Y AVG

-24.11%

CURRENT VS 15Y AVG

-23.64%

CURRENT VS 20Y AVG

+29.65%

SECTOR MEDIAN · HEALTHCARE

14.90%

median of 90 covered companies

CURRENT VS SECTOR MEDIAN

+71.54%

vs the sector median at left

NAME	MARKET CAP	OPERATING MARGIN	TTM	3Y	5Y
Regeneron Pharmaceuticals, Inc. (REGN)	$83.48B	25.56%	26.06%	27.73%	33.42%
HCA Healthcare, Inc. (HCA)vs ›	$87.04B	15.48%	15.38%	15.15%	15.20%
Elevance Health Inc. (ELV)vs ›	$87.17B	3.51%	4.55%	4.90%	5.40%
Cigna Corporation (CI)vs ›	$72.89B	3.46%	3.56%	4.04%	4.30%
GSK plc (GSK)vs ›	$97.25B	20.72%	19.17%	20.63%	20.79%
Boston Scientific Corporation (BSX)vs ›	$66.86B	21.46%	17.76%	16.30%	14.57%
Sanofi (SNY)vs ›	$103.62B	14.74%	18.46%	19.67%	22.87%
Cencora, Inc. (COR)vs ›	$63.17B	1.30%	1.08%	1.06%	1.09%
McKesson Corporation (MCK)vs ›	$104.10B	1.62%	1.41%	1.42%	1.37%
Stryker Corporation (SYK)vs ›	$105.97B	22.03%	20.93%	20.75%	21.02%

NAME

MARKET CAP

OPERATING MARGIN

TTM

Regeneron Pharmaceuticals, Inc. (REGN)

$83.48B

25.56%

26.06%

27.73%

33.42%

HCA Healthcare, Inc. (HCA)vs ›

$87.04B

15.48%

15.38%

15.15%

15.20%

Elevance Health Inc. (ELV)vs ›

$87.17B

3.51%

4.55%

4.90%

5.40%

Cigna Corporation (CI)vs ›

$72.89B

3.46%

3.56%

4.04%

4.30%

GSK plc (GSK)vs ›

$97.25B

20.72%

19.17%

20.63%

20.79%

Boston Scientific Corporation (BSX)vs ›

$66.86B

21.46%

17.76%

16.30%

14.57%

Sanofi (SNY)vs ›

$103.62B

14.74%

18.46%

19.67%

22.87%

Cencora, Inc. (COR)vs ›

$63.17B

1.30%

1.08%

1.06%

1.09%

McKesson Corporation (MCK)vs ›

$104.10B

1.62%

1.41%

1.42%

1.37%

Stryker Corporation (SYK)vs ›

$105.97B

22.03%

20.93%

20.75%

21.02%

Operating Margin FAQ

What is the operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The operating margin for REGN stock is 25.56%.

Is Regeneron Pharmaceuticals, Inc.'s operating margin high or low?

The operating margin of 25.56% is 24% below its 5-year average of 33.42%, near the low end of its 5-year range (17.83%–65.14%).

What is the TTM average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The TTM average operating margin for REGN stock is 26.06%.

What is the 3Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 3Y average operating margin for REGN stock is 27.73%.

What is the 5Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 5Y average operating margin for REGN stock is 33.42%.

What is the 10Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 10Y average operating margin for REGN stock is 33.68%.

What is the 15Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 15Y average operating margin for REGN stock is 33.47%.

What is the 20Y average operating margin for Regeneron Pharmaceuticals, Inc. (REGN)?

The 20Y average operating margin for REGN stock is 19.71%.

DATE	OPERATING MARGIN
2026-06-30	33.11%
2026-03-31	17.83%
2025-12-31	22.65%
2025-09-30	27.35%
2025-06-30	29.37%
2025-03-31	19.54%
2024-12-31	26.13%
2024-09-30	31.70%
2024-06-30	30.15%
2024-03-31	23.89%
2023-12-31	30.59%
2023-09-30	36.01%
2023-06-30	32.19%
2023-03-31	31.71%
2022-12-31	38.53%
2022-09-30	41.68%
2022-06-30	45.74%
2022-03-31	43.39%
2021-12-31	53.31%
2021-09-30	53.50%
2021-06-30	65.14%
2021-03-31	44.00%
2020-12-31	48.17%
2020-09-30	45.91%
2020-06-30	33.63%
2020-03-31	38.29%
2019-12-31	36.26%
2019-09-30	42.35%
2019-06-30	20.00%
2019-03-31	34.97%
2018-12-31	37.25%
2018-09-30	37.69%
2018-06-30	38.69%
2018-03-31	37.53%
2017-12-31	34.05%
2017-09-30	37.31%
2017-06-30	37.43%
2017-03-31	32.64%
2016-12-31	28.28%
2016-09-30	29.73%
2016-06-30	24.05%
2016-03-31	27.42%
2015-12-31	21.04%
2015-09-30	34.50%
2015-06-30	34.53%
2015-03-31	32.61%
2014-12-31	30.83%
2014-09-30	25.97%
2014-06-30	34.26%
2014-03-31	30.61%
2013-12-31	34.74%
2013-09-30	39.66%
2013-06-30	34.55%
2013-03-31	34.81%
2012-12-31	35.13%
2012-09-30	47.32%
2012-06-30	29.66%
2012-03-31	9.58%
2011-12-31	-36.92%
2011-09-30	-56.85%
2011-06-30	-55.95%
2011-03-31	-36.52%
2010-12-31	7.76%
2010-09-30	-30.28%
2010-06-30	-20.47%
2010-03-31	-27.68%
2009-12-31	-40.71%
2009-09-30	-1.10%
2009-06-30	-18.07%
2009-03-31	-22.86%
2008-12-31	-61.96%
2008-09-30	-30.39%
2008-06-30	-32.35%
2008-03-31	-28.22%
2007-12-31	-17.82%
2007-09-30	-173.31%
2007-06-30	-137.89%
2007-03-31	-213.13%
2006-12-31	-323.66%
2006-09-30	-180.86%
2006-06-30	-125.92%
2006-03-31	-118.90%
2005-12-31	-156.76%
2005-09-30	-212.34%
2005-06-30	-196.55%
2005-03-31	-174.84%
2004-12-31	8.44%
2004-09-30	-25.96%
2004-06-30	-44.49%
2004-03-31	38.38%
2003-12-31	380.85%
2003-09-30	-147.79%
2003-06-30	-255.72%
2003-03-31	-279.98%
2002-12-31	1263.09%
2002-09-30	-490.05%

DATE

OPERATING MARGIN

2026-06-30

33.11%

2026-03-31

17.83%

2025-12-31

22.65%

2025-09-30

27.35%

2025-06-30

29.37%

2025-03-31

19.54%

2024-12-31

26.13%

2024-09-30

31.70%

2024-06-30

30.15%

2024-03-31

23.89%

2023-12-31

30.59%

2023-09-30

36.01%

2023-06-30

32.19%

2023-03-31

31.71%

2022-12-31

38.53%

2022-09-30

41.68%

2022-06-30

45.74%

2022-03-31

43.39%

2021-12-31

53.31%

2021-09-30

53.50%

2021-06-30

65.14%

2021-03-31

44.00%

2020-12-31

48.17%

2020-09-30

45.91%

2020-06-30

33.63%

2020-03-31

38.29%

2019-12-31

36.26%

2019-09-30

42.35%

2019-06-30

20.00%

2019-03-31

34.97%

2018-12-31

37.25%

2018-09-30

37.69%

2018-06-30

38.69%

2018-03-31

37.53%

2017-12-31

34.05%

2017-09-30

37.31%

2017-06-30

37.43%

2017-03-31

32.64%

2016-12-31

28.28%

2016-09-30

29.73%

2016-06-30

24.05%

2016-03-31

27.42%

2015-12-31

21.04%

2015-09-30

34.50%

2015-06-30

34.53%

2015-03-31

32.61%

2014-12-31

30.83%

2014-09-30

25.97%

2014-06-30

34.26%

2014-03-31

30.61%

2013-12-31

34.74%

2013-09-30

39.66%

2013-06-30

34.55%

2013-03-31

34.81%

2012-12-31

35.13%

2012-09-30

47.32%

2012-06-30

29.66%

2012-03-31

9.58%

2011-12-31

-36.92%

2011-09-30

-56.85%

2011-06-30

-55.95%

2011-03-31

-36.52%

2010-12-31

7.76%

2010-09-30

-30.28%

2010-06-30

-20.47%

2010-03-31

-27.68%

2009-12-31

-40.71%

2009-09-30

-1.10%

2009-06-30

-18.07%

2009-03-31

-22.86%

2008-12-31

-61.96%

2008-09-30

-30.39%

2008-06-30

-32.35%

2008-03-31

-28.22%

2007-12-31

-17.82%

2007-09-30

-173.31%

2007-06-30

-137.89%

2007-03-31

-213.13%

2006-12-31

-323.66%

2006-09-30

-180.86%

2006-06-30

-125.92%

2006-03-31

-118.90%

2005-12-31

-156.76%

2005-09-30

-212.34%

2005-06-30

-196.55%

2005-03-31

-174.84%

2004-12-31

8.44%

2004-09-30

-25.96%

2004-06-30

-44.49%

2004-03-31

38.38%

2003-12-31

380.85%

2003-09-30

-147.79%

2003-06-30

-255.72%

2003-03-31

-279.98%

2002-12-31

1263.09%

2002-09-30

-490.05%

Operating Margin: 25.56%

REGN Operating Margin

REGN Average Operating Margin Chart

REGN Current vs Average Operating Margin Chart

REGN Operating Margin Metrics

REGN Competitors' Operating Margin

Operating Efficiency

Operating Margin Formula & Definition

Operating Margin FAQ

REGN Operating Margin History

Related Metrics